KEYMED BIOSCIENCES -0001 (64Z) - Total Liabilities
Based on the latest financial reports, KEYMED BIOSCIENCES -0001 (64Z) has total liabilities worth €1.44 Billion EUR (≈ $1.69 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore KEYMED BIOSCIENCES -0001 net asset momentum to track the company's year-over-year net asset growth rate.
KEYMED BIOSCIENCES -0001 - Total Liabilities Trend (2021–2025)
This chart illustrates how KEYMED BIOSCIENCES -0001's total liabilities have evolved over time, based on quarterly financial data.
KEYMED BIOSCIENCES -0001 Competitors by Total Liabilities
The table below lists competitors of KEYMED BIOSCIENCES -0001 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zibo Qixiang Tengda Chemical Co Ltd
SHE:002408
|
China | CN¥14.47 Billion |
|
Sezzle Inc.
NASDAQ:SEZL
|
USA | $211.69 Million |
|
Shenzhen Click Technology Co Ltd
SHE:002782
|
China | CN¥2.58 Billion |
|
LeMaitre Vascular Inc
NASDAQ:LMAT
|
USA | $222.90 Million |
|
Weichai Heavy Machinery Co Ltd
SHE:000880
|
China | CN¥5.69 Billion |
|
MeHow Innovative Ltd. A
SHE:301363
|
China | CN¥467.62 Million |
|
ISC Co. Ltd
KQ:095340
|
Korea | ₩78.49 Billion |
|
Ströer SE & Co. KGaA
F:SAX
|
Germany | €2.39 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down KEYMED BIOSCIENCES -0001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 64Z market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how KEYMED BIOSCIENCES -0001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for KEYMED BIOSCIENCES -0001 (2021–2025)
The table below shows the annual total liabilities of KEYMED BIOSCIENCES -0001 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.44 Billion ≈ $1.69 Billion |
+11.71% |
| 2024-12-31 | €1.29 Billion ≈ $1.51 Billion |
+44.11% |
| 2023-12-31 | €896.11 Million ≈ $1.05 Billion |
+51.09% |
| 2022-12-31 | €593.10 Million ≈ $693.39 Million |
+105.17% |
| 2021-12-31 | €289.07 Million ≈ $337.96 Million |
-- |
About KEYMED BIOSCIENCES -0001
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China and internationally. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), chronic rhinosinusitis with nasal polyposis (CRSwNP), seasonal allergic rhinitis, prurigo nodula… Read more